These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11729859)

  • 1. The association between telomerase activity and hormone receptor status and p53 expression in breast cancer.
    Mokbel K; Ghilchik M; Williams G; Akbar N; Parris C; Newbold R
    Int J Surg Investig; 2000; 1(6):509-16. PubMed ID: 11729859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomerase activity and Bcl-2 expression in human breast cancer.
    Elkak AE; Kirkpatrick K; Mears L; Wells C; Ghilchik M; Newbold R; Mokbel K
    Eur J Surg Oncol; 2002 Feb; 28(1):14-8. PubMed ID: 11869007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical implications of telomerase activity in breast cancer fine-needle aspirates].
    Jin S; Zhang W; Teng M
    Zhonghua Zhong Liu Za Zhi; 2000 Mar; 22(2):132-4. PubMed ID: 11776640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study.
    Ostrowski JL; Sawan A; Henry L; Wright C; Henry JA; Hennessy C; Lennard TJ; Angus B; Horne CH
    J Pathol; 1991 May; 164(1):75-81. PubMed ID: 2056391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging role of p53, bcl-2 and telomerase activity in Egyptian breast cancer patients.
    Swellam M; Ismail M; Eissa S; Hamdy M; Mokhtar N
    IUBMB Life; 2004 Aug; 56(8):483-90. PubMed ID: 15545228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
    J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of human telomerase reverse transcriptase gene and protein, and of estrogen and progesterone receptors, in breast tumors: preliminary data from neo-adjuvant chemotherapy.
    Kammori M; Izumiyama N; Hashimoto M; Nakamura K; Okano T; Kurabayashi R; Naoki H; Honma N; Ogawa T; Kaminishi M; Takubo K
    Int J Oncol; 2005 Nov; 27(5):1257-63. PubMed ID: 16211220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer.
    Neven P; Van Calster B; Van den Bempt I; Van Huffel S; Van Belle V; Hendrickx W; Decock J; Wildiers H; Paridaens R; Amant F; Leunen K; Berteloot P; Timmerman D; Van Limbergen E; Weltens C; Van den Bogaert W; Smeets A; Vergote I; Christiaens MR; Drijkoningen M
    Breast Cancer Res Treat; 2008 Jul; 110(1):153-9. PubMed ID: 17687649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.
    Van Calster B; Vanden Bempt I; Drijkoningen M; Pochet N; Cheng J; Van Huffel S; Hendrickx W; Decock J; Huang HJ; Leunen K; Amant F; Berteloot P; Paridaens R; Wildiers H; Van Limbergen E; Weltens C; Timmerman D; Van Gorp T; Smeets A; Van den Bogaert W; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 Jan; 113(1):181-7. PubMed ID: 18264760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 expression in breast cancer related to prognostic factors.
    Ciesielski D; Dziewulska-Bokiniec A; Zółtowska A; Roszkiewicz A; Kopacz A; Wojtacki J
    Neoplasma; 1995; 42(5):235-7. PubMed ID: 8552201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
    Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
    Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on p53 immunolocalisation in breast cancer and its prognostic significance.
    Meenakshi A; Manoharan V
    Hum Antibodies; 1999; 9(3):171-6. PubMed ID: 10690631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 protein expression in human breast carcinoma: lack of prognostic potential for recurrence of the disease.
    Katoh A; Breier S; Stemmler N; Specht S; Blanock K; D'Amico F
    Anticancer Res; 1996; 16(3A):1301-4. PubMed ID: 8702254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
    Missmer SA; Eliassen AH; Barbieri RL; Hankinson SE
    J Natl Cancer Inst; 2004 Dec; 96(24):1856-65. PubMed ID: 15601642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in oestrogen and progesterone receptors, HER-2, p53 expression and proliferation in ductal breast cancers in relation to histopathological grade.
    Zasławski R; Surowiak P; Paluchowski P; Dziegiel P; Maciejczyk A; Pudełko M; Wojnar A; Zabel M
    Folia Morphol (Warsz); 2005 Feb; 64(1):9-15. PubMed ID: 15832264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.